Optimizing the selection of kinase inhibitors for chronic myeloid leukemia patients

被引：0

作者：

Hiwase, Devendra K. ^{[1
,2
]}

Yeung, David T. ^{[1
,2
]}

White, Deborah L. ^{[1
,2
,3
]}

机构：

[1] SA Pathol, Div Hematol, Adelaide, SA 5000, Australia

[2] Ctr Canc Biol, Adelaide, SA 5000, Australia

[3] Univ Adelaide, Adelaide, SA 5000, Australia

来源：

EXPERT REVIEW OF HEMATOLOGY | 2011年 / 4卷 / 03期

关键词：

CML; dasatinib; imatinib; nilotinib; TKI; CHRONIC MYELOGENOUS LEUKEMIA; HIGH-DOSE IMATINIB; ACUTE LYMPHOBLASTIC-LEUKEMIA; BCR-ABL MUTATIONS; IN-VITRO SENSITIVITY; FRONT-LINE TREATMENT; EARLY CHRONIC PHASE; CYTOGENETIC RESPONSES; DOMAIN MUTATIONS; CLINICAL RESISTANCE;

D O I：

10.1586/EHM.11.19

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Long-term follow-up of clinical studies has demonstrated the efficacy of imatinib therapy in newly diagnosed chronic phase-chronic myeloid leukemia patients (CML). However, recent updates of two separate randomized Phase III studies demonstrated higher complete cytogenetic and major molecular response rates with dasatinib and nilotinib compared with imatinib 400 mg/day. Hence, for newly diagnosed chronic phase-CML patients there are multiple treatment options, including standard-dose imatinib, high-dose imatinib, and combination therapy of imatinib and interferon, dasatinib and nilotinib. This article critically analyzes the current literature and provides guidelines for the management of newly diagnosed CML. Disease and therapy-related prognostic factors, which may aid in the selection of therapeutic strategies to enable optimal treatment outcomes, are discussed. In addition, we provide commentary on the therapeutic options for patients who fail imatinib therapy.

引用

页码：285 / 299

页数：15

共 106 条

[1] Significance of Suboptimal Response to Imatinib, as Defined by the European LeukemiaNet, in the Long-Term Outcome of Patients With Early Chronic Myeloid Leukemia in Chronic Phase [J].

Alvarado, Yesid ;

Kantarjian, Hagop ;

O'Brien, Susan ;

Faderl, Stefan ;

Borthakur, Gautam ;

Burger, Jan ;

Wierda, William ;

Garcia-Manero, Guillermo ;

Shan, Jianqin ;

Cortes, Jorge .

CANCER, 2009, 115 (16) :3709-3718

[2] Part I: Mechanisms of resistance to imatinib in chronic myeloid leukaemia [J].

Apperley, Jane F. .

LANCET ONCOLOGY, 2007, 8 (11) :1018-1029

[3] Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet [J].

Baccarani, Michele ;

Saglio, Giuseppe ;

Goldman, John ;

Hochhaus, Andreas ;

Simonsson, Bengt ;

Appelbaum, Frederick ;

Apperley, Jane ;

Cervantes, Francisco ;

Cortes, Jorge ;

Deininger, Michael ;

Gratwohl, Alois ;

Guilhot, Frangois ;

Horowitz, Mary ;

Hughes, Timothy ;

Kantarjian, Hagop ;

Larson, Richard ;

Niederwieser, Dielger ;

Silver, Richard ;

Hehlmann, Rudiger .

BLOOD, 2006, 108 (06) :1809-1820

[4] Chronic Myeloid Leukemia: An Update of Concepts and Management Recommendations of European LeukemiaNet [J].

Baccarani, Michele ;

Cortes, Jorge ;

Pane, Fabrizio ;

Niederwieser, Dietger ;

Saglio, Giuseppe ;

Apperley, Jane ;

Cervantes, Francisco ;

Deininger, Michael ;

Gratwohl, Alois ;

Guilhot, Francois ;

Hochhaus, Andreas ;

Horowitz, Mary ;

Hughes, Timothy ;

Kantarjian, Hagop ;

Larson, Richard ;

Radich, Jerald ;

Simonsson, Bengt ;

Silver, Richard T. ;

Goldman, John ;

Hehlmann, Rudiger .

JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (35) :6041-6051

[5] Comparison of imatinib 400 mg and 800 mg daily in the front-line treatment of high-risk, Philadelphia-positive chronic myeloid leukemia: a European LeukemiaNet Study [J].

Baccarani, Michele ;

Rosti, Gianantonio ;

Castagnetti, Fausto ;

Haznedaroglu, Ibrahim ;

Porkka, Kimmo ;

Abruzzese, Elisabetta ;

Alimena, Giuliana ;

Ehrencrona, Hans ;

Hjorth-Hansen, Henrik ;

Kairisto, Veli ;

Levato, Luciano ;

Martinelli, Giovanni ;

Nagler, Arnon ;

Nielsen, Johan Lanng ;

Ozbek, Ugur ;

Palandri, Francesca ;

Palmieri, Fausto ;

Pane, Fabrizio ;

Rege-Cambrin, Giovanna ;

Russo, Domenico ;

Specchia, Giorgina ;

Testoni, Nicoletta ;

Weiss-Bjerrum, Ole ;

Saglio, Giuseppe ;

Simonsson, Bengt .

BLOOD, 2009, 113 (19) :4497-4504

[6] High frequency of point mutations clustered within the adenosine triphosphate-binding region of BCR/ABL in patients with chronic myeloid leukemia or Ph-positive acute lymphoblastic leukemia who develop imatinib (STI571) resistance [J].

Branford, S ;

Rudzki, Z ;

Walsh, S ;

Grigg, A ;

Arthur, C ;

Taylor, K ;

Herrmann, R ;

Lynch, KP ;

Hughes, TP .

BLOOD, 2002, 99 (09) :3472-3475

[7] Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis [J].

Branford, S ;

Rudzki, Z ;

Walsh, S ;

Parkinson, I ;

Grigg, A ;

Szer, J ;

Taylor, K ;

Herrmann, R ;

Seymour, JF ;

Arthur, C ;

Joske, D ;

Lynch, K ;

Hughes, T .

BLOOD, 2003, 102 (01) :276-283

[8] Real-time quantitative PCR analysis can be used as a primary screen to identify patients with CML treated with imatinib who have BCR-ABL kinase domain mutations [J].

Branford, S ;

Rudzki, Z ;

Parkinson, I ;

Grigg, A ;

Taylor, K ;

Seymour, JF ;

Durrant, S ;

Browett, P ;

Schwarer, AP ;

Arthur, C ;

Catalano, J ;

Leahy, MF ;

Filshie, R ;

Bradstock, K ;

Herrmann, R ;

Joske, D ;

Lynch, K ;

Hughes, T .

BLOOD, 2004, 104 (09) :2926-2932

[9]

Branford S, 2010, ASH ANN M, V116, P889

[10]

Branford S, 2009, 51 ANN M AM SOC HEM

← 1 2 3 4 5 6 7 8 9 10 →